Drug
Miricorilant
Miricorilant: highest development phase Phase 2, developed by Corcept Therapeutics. 7 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Corcept Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Miricorilant NCT03823703 | Phase 2 | Nonalcoholic Steatohepatitis (NASH) |
| Miricorilant (Cohort A) NCT06108219 | Phase 2 | Nonalcoholic Steatohepatitis (NASH) |
| Miricorilant NCT07553663 | Phase 1 | Nonalcoholic Steatohepatitis (NASH) |
| Miricorilant NCT05553470 | Phase 1 | Non-alcoholic Steatohepatitis (NASH) |
| Miricorilant 300 mg tablets NCT04672499 | Phase 1 | Healthy |
| Miricorilant NCT05712265 | Phase 1 | Antipsychotic Induced Weight Gain |
| Miricorilant NCT06947304 | Phase 1 | Nonalcoholic Steatohepatitis (NASH) |
Latest
No recent events.
Follow Miricorilant on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.